PH1 (Agxt knockout) and hydroxyproline-induced mouse models with mouse-active analog DCR-m355; LDHA knockdown in monkeys
“In a mouse model of PH1 with knockout of the alanine-glyoxylate aminotransferase gene involved in limiting glyoxylate oxidation to oxalate, administration of the mouse active analog of nedosiran (DCR-m355) at doses of 0.5, 1, and 5 mg/kg caused dose-dependent suppression of hepatic LDH protein”
LDHA target sequence conserved in primates but not mice, so nedosiran is inactive in mice
“The target sequence of nedosiran in LDHA mRNA is conserved in humans and nonhuman primates, but not in mice; thus, nedosiran is fully active in cynomolgus monkeys but inactive in mice.”
FDA: nonclinical pharmacology supports proof of concept and the clinical dosing regimen
“The nonclinical pharmacology data support proof of concept, as well as the dosing regimen of nedosiran that was evaluated in the clinical studies based on the following data:”